21 CFR · Food and Drugs
§ 516.1287 — Lotilaner, moxidectin, praziquantel, and pyrantel.
eCFR · current through Jul 29, 2026
§ 516.1287 Lotilaner, moxidectin, praziquantel, and pyrantel.
(a)Specifications. Each chewable tablet contains:
(1)56.25 milligrams (mg) lotilaner, 0.056 mg moxidectin, 14.25 mg praziquantel, and 14.25 mg pyrantel (as pamoate salt);
(2)112.5 mg lotilaner, 0.113 mg moxidectin, 28.5 mg praziquantel, and 28.5 mg pyrantel (as pamoate salt);
(3)225 mg lotilaner, 0.225 mg moxidectin, 57 mg praziquantel, and 57 mg pyrantel (as pamoate salt);
(4)450 mg lotilaner, 0.45 mg moxidectin, 114 mg praziquantel, and 114 mg pyrantel (as pamoate salt); or
(5)900 mg lotilaner, 0.9 mg moxidectin, 228 mg praziquantel, and 228 mg pyrantel (as pamoate salt).
(b)Sponsor. See No. 058198 in § 510.600(c) of this chapter.
(c)Conditions of use—
(1)Amount. Administer orally at the minimum dosage of 9 mg/p
Free access — add to your briefcase to read the full text and ask questions with AI
21 C.F.R. § 516.1287 (Lotilaner, moxidectin, praziquantel, and pyrantel.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Related
§ 510.600
21 C.F.R. § 510.600
Nearby Sections
11
§ 516.498
Crofelemer.§ 516.570
Doramectin.§ 516.900
Fluralaner.§ 516.1012
Fuzapladib.§ 516.1449
Molidustat oral suspension.§ 516.1760
Phenobarbital.§ 516.1780
Pimobendan.§ 516.2106
Sirolimus.§ 516.2475
Torsemide.